US4522811A
(en)
|
1982-07-08 |
1985-06-11 |
Syntex (U.S.A.) Inc. |
Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
|
US5670527A
(en)
|
1993-07-16 |
1997-09-23 |
Smithkline Beecham Corporation |
Pyridyl imidazole compounds and compositions
|
US5593992A
(en)
|
1993-07-16 |
1997-01-14 |
Smithkline Beecham Corporation |
Compounds
|
US5658903A
(en)
|
1995-06-07 |
1997-08-19 |
Smithkline Beecham Corporation |
Imidazole compounds, compositions and use
|
US6369068B1
(en)
|
1995-06-07 |
2002-04-09 |
Smithkline Beecham Corporation |
Amino substituted pyrimidine containing compounds
|
ZA97175B
(en)
|
1996-01-11 |
1997-11-04 |
Smithkline Beecham Corp |
Novel substituted imidazole compounds.
|
AP9700912A0
(en)
|
1996-01-11 |
1997-01-31 |
Smithkline Beecham Corp |
Novel cycloalkyl substituted imidazoles
|
JP2001508395A
(ja)
|
1996-01-11 |
2001-06-26 |
スミスクライン・ビーチャム・コーポレイション |
新規シクロアルキル置換イミダゾール
|
EP1005343A1
(en)
|
1996-03-08 |
2000-06-07 |
Smithkline Beecham Corporation |
Use of csaid?tm compounds as inhibitors of angiogenesis
|
US6218136B1
(en)
|
1996-03-12 |
2001-04-17 |
Smithkline Beecham Corporation |
Methods of the identification of pharmaceutically active compounds
|
US6096748A
(en)
|
1996-03-13 |
2000-08-01 |
Smithkline Beecham Corporation |
Pyrimidine compounds useful in treating cytokine mediated diseases
|
WO1997035855A1
(en)
|
1996-03-25 |
1997-10-02 |
Smithkline Beecham Corporation |
Novel treatment for cns injuries
|
US6096739A
(en)
|
1996-03-25 |
2000-08-01 |
Smithkline Beecham Corporation |
Treatment for CNS injuries
|
WO1998007425A1
(en)
|
1996-08-21 |
1998-02-26 |
Smithkline Beecham Corporation |
Imidazole compounds, compositions and use
|
US6096753A
(en)
|
1996-12-05 |
2000-08-01 |
Amgen Inc. |
Substituted pyrimidinone and pyridone compounds and methods of use
|
US6147080A
(en)
|
1996-12-18 |
2000-11-14 |
Vertex Pharmaceuticals Incorporated |
Inhibitors of p38
|
WO1998028292A1
(en)
|
1996-12-23 |
1998-07-02 |
Smithkline Beecham Corporation |
Novel piperidine containing compounds
|
DE69816109T2
(de)
|
1997-04-24 |
2004-04-22 |
Ortho-Mcneil Pharmaceutical, Inc. |
Substituierte imidazole zur behandlung von entzündlichen krankheiten
|
US6514977B1
(en)
|
1997-05-22 |
2003-02-04 |
G.D. Searle & Company |
Substituted pyrazoles as p38 kinase inhibitors
|
EP1023066A4
(en)
|
1997-06-13 |
2001-05-23 |
Smithkline Beecham Corp |
NEW PYRAZOLE AND PYRAZOLINE SUBSTITUTED COMPOUND
|
CA2294137A1
(en)
|
1997-06-19 |
1998-12-23 |
Smithkline Beecham Corporation |
Novel aryloxy substituted pyrimidine imidazole compounds
|
US6093742A
(en)
|
1997-06-27 |
2000-07-25 |
Vertex Pharmaceuticals, Inc. |
Inhibitors of p38
|
TW517055B
(en)
|
1997-07-02 |
2003-01-11 |
Smithkline Beecham Corp |
Novel substituted imidazole compounds
|
AR016294A1
(es)
|
1997-07-02 |
2001-07-04 |
Smithkline Beecham Corp |
Compuesto de imidazol sustituido, composicion farmaceutica que la contiene, su uso en la fabricacion de un medicamento y procedimiento para supreparacion
|
GB9721437D0
(en)
|
1997-10-10 |
1997-12-10 |
Glaxo Group Ltd |
Heteroaromatic compounds and their use in medicine
|
JP3579350B2
(ja)
|
1997-10-20 |
2004-10-20 |
エフ.ホフマン−ラ ロシュ アーゲー |
二環式キナーゼ阻害剤
|
US6162613A
(en)
|
1998-02-18 |
2000-12-19 |
Vertex Pharmaceuticals, Inc. |
Methods for designing inhibitors of serine/threonine-kinases and tyrosine kinases
|
JP3590586B2
(ja)
|
1998-05-05 |
2004-11-17 |
エフ.ホフマン−ラ ロシュ アーゲー |
P−38mapキナーゼインヒビターとしてのピラゾール誘導体
|
US6316466B1
(en)
|
1998-05-05 |
2001-11-13 |
Syntex (U.S.A.) Llc |
Pyrazole derivatives P-38 MAP kinase inhibitors
|
MY132496A
(en)
|
1998-05-11 |
2007-10-31 |
Vertex Pharma |
Inhibitors of p38
|
PL344330A1
(en)
|
1998-05-22 |
2001-10-22 |
Smithkline Beecham Corp |
Novel 2-alkyl substituted imidazole compounds
|
KR100605140B1
(ko)
|
1998-05-22 |
2006-07-28 |
싸이오스 인크 |
심장병 및 다른 질병을 치료하기 위한 헤테로 고리 화합물및 그 치료 방법
|
US6340685B1
(en)
|
1998-05-22 |
2002-01-22 |
Scios, Inc. |
Compounds and methods to treat cardiac failure and other disorders
|
US6448257B1
(en)
|
1998-05-22 |
2002-09-10 |
Scios, Inc. |
Compounds and methods to treat cardiac failure and other disorders
|
US6867209B1
(en)
|
1998-05-22 |
2005-03-15 |
Scios, Inc. |
Indole-type derivatives as inhibitors of p38 kinase
|
US6589954B1
(en)
|
1998-05-22 |
2003-07-08 |
Scios, Inc. |
Compounds and methods to treat cardiac failure and other disorders
|
WO1999064400A1
(en)
|
1998-06-12 |
1999-12-16 |
Vertex Pharmaceuticals Incorporated |
INHIBITORS OF p38
|
WO2000010563A1
(en)
|
1998-08-20 |
2000-03-02 |
Smithkline Beecham Corporation |
Novel substituted triazole compounds
|
US6184226B1
(en)
|
1998-08-28 |
2001-02-06 |
Scios Inc. |
Quinazoline derivatives as inhibitors of P-38 α
|
EP1114039A1
(en)
|
1998-09-18 |
2001-07-11 |
Vertex Pharmaceuticals Incorporated |
INHIBITORS OF p38
|
EP1119254A4
(en)
|
1998-10-07 |
2004-05-12 |
Smithkline Beecham Corp |
STROKE TREATMENT
|
WO2000025791A1
(en)
|
1998-11-04 |
2000-05-11 |
Smithkline Beecham Corporation |
Pyridin-4-yl or pyrimidin-4-yl substituted pyrazines
|
UA73492C2
(en)
|
1999-01-19 |
2005-08-15 |
|
Aromatic heterocyclic compounds as antiinflammatory agents
|
DE60033028T2
(de)
|
1999-04-23 |
2007-11-15 |
Takeda Pharmaceutical Co. Ltd. |
5-pyridyl-1,3-azol-derivate, verfahren zu ihrer herstellung und ihre verwendung
|
ATE376547T1
(de)
|
1999-05-21 |
2007-11-15 |
Scios Inc |
Derivate des indol-typs als p38 kinase inhibitoren
|
MXPA02000314A
(es)
|
1999-07-09 |
2004-06-22 |
Boehringer Ingelheim Pharma |
Proceso novedoso para la sintesis de compuestos de urea substituidos con heteroarilo.
|
US6541477B2
(en)
|
1999-08-27 |
2003-04-01 |
Scios, Inc. |
Inhibitors of p38-a kinase
|
HUP0204333A3
(en)
|
1999-09-17 |
2004-07-28 |
Smithkline Beecham Corp |
Use of csaids in rhinovirus infection
|
ES2277858T3
(es)
|
1999-10-21 |
2007-08-01 |
F. Hoffmann-La Roche Ag |
Heterociclos de nitrogeno biciclicos alquilamino sustituidos como inhibidores de proteina kinasa p38.
|
CZ20021744A3
(cs)
|
1999-10-21 |
2002-08-14 |
F. Hoffmann-La Roche Ag |
Bicyklické dusíkové heterocykly substituované heteroalkylaminoskupinou jako inhibitory P38 proteinkinázy
|
EP1248624A4
(en)
|
1999-11-23 |
2003-01-22 |
Smithkline Beecham Corp |
3,4-DIHYDRO- (1H) -CHIRAZOLINE-2-ONES AND THE USE THEREOF AS CSBP / P38 KINASE INHIBITORS
|
ATE296809T1
(de)
|
1999-11-23 |
2005-06-15 |
Smithkline Beecham Corp |
3,4-dihydro-(1h)chinazolin-2-on-verbindungen als csbp/p38-kinase-inhibitoren
|
US7053099B1
(en)
|
1999-11-23 |
2006-05-30 |
Smithkline Beecham Corporation |
3,4-dihydro-(1H)quinazolin-2-one compounds as CSBP/p38 kinase inhibitors
|
AU1782301A
(en)
|
1999-11-23 |
2001-06-04 |
Smithkline Beecham Corporation |
3,4-dihydro-(1h)quinazolin-2-one compounds as csbp/p39 kinase inhibitors
|
EP1242385B1
(en)
|
1999-12-28 |
2009-11-25 |
Pharmacopeia, Inc. |
Cytokine, especially tnf-alpha, inhibitors
|
US6906067B2
(en)
|
1999-12-28 |
2005-06-14 |
Bristol-Myers Squibb Company |
N-heterocyclic inhibitors of TNF-α expression
|
AU2001241927A1
(en)
|
2000-02-28 |
2001-09-12 |
Scios Inc. |
Inhibitors of p38-alpha kinase
|
MY141144A
(en)
|
2000-03-02 |
2010-03-15 |
Smithkline Beecham Corp |
1, 5-disubstituted-3,4-dihydro-1h-pyrimido 4,5-dipyrimidin-2-one compounds and their use in treating csbp/p38 kinase mediated diseases
|
MXPA02012909A
(es)
|
2000-07-24 |
2004-05-05 |
Boehringer Ingelheim Pharma |
Formulaciones mejoradas de dosis oral de 1-(5-ter-butil -2-p-tiolil2h -pirazol-3 -il)-3-(4-2 (2-morfolin-4-il -etoxi) -naftalen -1-il) -urea.
|
PE20020506A1
(es)
|
2000-08-22 |
2002-07-09 |
Glaxo Group Ltd |
Derivados de pirazol fusionados como inhibidores de la proteina cinasa
|
EP1315727B1
(en)
|
2000-08-31 |
2005-06-29 |
F. Hoffmann-La Roche Ag |
7-oxo pyridopyrimidines
|
BR0113628A
(pt)
|
2000-08-31 |
2003-07-01 |
Hoffmann La Roche |
7-oxo-piridopirimidinas como inibidores de uma proliferação celular
|
JP2004530648A
(ja)
|
2000-10-19 |
2004-10-07 |
スミスクライン・ビーチャム・コーポレイション |
炎症により促進される咳の治療のためのp38阻害剤の使用
|
WO2002032862A2
(en)
|
2000-10-19 |
2002-04-25 |
Smithkline Beecham Corporation |
Use of p38 inhibitors for the treatment of smoke inhalation
|
ATE521353T1
(de)
|
2000-10-23 |
2011-09-15 |
Glaxosmithkline Llc |
Neues trisubstitutiertes 8h-pyridoä2,3- düpyrimidin-7-onderivat zur behandlung von durch csbp/p38kinase vermittelten krankheiten
|
AU2002232760B2
(en)
|
2000-11-17 |
2006-12-14 |
Bristol-Myers Squibb Company |
Methods of treating p38 kinase-associated conditions and pyrrolotriazine compounds useful as kinase inhibitors
|
EP1339708A2
(en)
|
2000-11-20 |
2003-09-03 |
Scios Inc. |
Indole-type inhibitors of p38 kinase
|
WO2002046158A2
(en)
|
2000-11-20 |
2002-06-13 |
Scios Inc. |
Piperidine/piperazine-type inhibitors of p38 kinase
|
WO2002042292A2
(en)
|
2000-11-20 |
2002-05-30 |
Scios Inc. |
Indol derivative and their use as inhibitors of p38 kinase
|
US20020165286A1
(en)
|
2000-12-08 |
2002-11-07 |
Hanne Hedeman |
Dermal anti-inflammatory composition
|
CA2431904A1
(en)
|
2000-12-20 |
2002-08-01 |
Merck & Co., Inc. |
(halo-benzo carbonyl)heterocyclo fused phenyl p38 kinase inhibiting agents
|
ATE305303T1
(de)
|
2001-02-12 |
2005-10-15 |
Hoffmann La Roche |
6-substituierte pyridopyrimidine
|
IL157541A0
(en)
|
2001-02-28 |
2004-03-28 |
Univ Temple |
METHOD FOR PROTECTING CELLS AND TISSUES FORM IONIZING RADIATION TOXICITY WITH alpha, beta UNSATURATED ARYL SULFONES
|
OA12552A
(en)
|
2001-03-09 |
2006-06-06 |
Pfizer Prod Inc |
Triazolopyridines as anti-inflammatory agents.
|
CA2440211A1
(en)
|
2001-03-09 |
2002-09-19 |
Pfizer Products Inc. |
Benzimidazole anti-inflammatory compounds
|
WO2002076463A1
(en)
|
2001-03-23 |
2002-10-03 |
Smithkline Beecham Corporation |
Compounds useful as kinase inhibitors for the treatment of hyperproliferative diseases
|
WO2002076985A1
(en)
|
2001-03-23 |
2002-10-03 |
Smithkline Beecham Corporation |
Compounds useful as kinase inhibitors for the treatment of hyperproliferative diseases
|
WO2002076954A1
(en)
|
2001-03-23 |
2002-10-03 |
Smithkline Beecham Corporation |
Compounds useful as kinase inhibitors for the treatment of hyperproliferative diseases
|
WO2002076984A1
(en)
|
2001-03-23 |
2002-10-03 |
Smithkline Beecham Corporation |
Compounds useful as kinase inhibitors for the treatment of hyperproliferative diseases
|
WO2002076396A2
(en)
|
2001-03-23 |
2002-10-03 |
Smithkline Beecham Corporation |
Compounds useful as kinase inhibitors for the treatment of hyperproliferative diseases
|
ATE304009T1
(de)
|
2001-04-04 |
2005-09-15 |
Pfizer Prod Inc |
Neue benzotriazole mit entzündungshemmender wirkung
|
WO2002085405A2
(en)
|
2001-04-24 |
2002-10-31 |
Merck Patent Gmbh |
COMBINATION THERAPY USING ANTI-ANGIOGENIC AGENTS AND TNF$g(a)
|
WO2002090360A1
(en)
|
2001-05-10 |
2002-11-14 |
Smithkline Beecham Corporation |
Compounds useful as kinase inhibitors for the treatment of hyperproliferative diseases
|
EP1392300A1
(en)
|
2001-05-11 |
2004-03-03 |
Vertex Pharmaceuticals Incorporated |
2,5-disubstituted pyridine, pyrimidine, pyridazine and 1, 2, 4-triazine derivatives for use as p38 inhibitors
|
PT1397364E
(pt)
|
2001-05-24 |
2007-10-22 |
Lilly Co Eli |
Novos derivados de pirrole como agentes farmacêuticos
|
EP2036891A3
(en)
|
2001-06-11 |
2009-03-25 |
Vertex Pharmaceuticals Incorporated |
Isoquinoline inhibitors of P38
|
CA2450555A1
(en)
|
2001-06-25 |
2003-01-03 |
Merck & Co., Inc. |
(pyrimidyl)(phenyl)substituted fused heteroaryl p38 inhibiting and pkg kinase inhibiting compounds
|
WO2003002544A1
(en)
|
2001-06-26 |
2003-01-09 |
Bristol-Myers Squibb Company |
N-heterocyclic inhibitors of tnf-alpha expression
|
CA2453147A1
(en)
|
2001-07-11 |
2003-01-23 |
Boehringer Ingelheim Pharmaceuticals, Inc. |
Methods of treating cytokine mediated diseases
|
WO2003015828A1
(en)
|
2001-08-20 |
2003-02-27 |
Boehringer Ingelheim Pharmaceuticals, Inc. |
Parenteral formulations of 1-(5-tert-butyl-2-p-tolyl-2h-pryrazol-3-yl)-3-[4-(2-morpholin-4-yl-ethoxy)-naphthalen-1-yl]-urea and a cyclodextrin
|
CN1281603C
(zh)
|
2001-08-30 |
2006-10-25 |
霍夫曼-拉罗奇有限公司 |
作为抗炎药的氨基吡咯化合物
|
CA2459943A1
(en)
|
2001-09-21 |
2003-04-03 |
Merck & Co., Inc. |
Androstanes as androgen receptor modulators
|
US7205275B2
(en)
|
2001-10-11 |
2007-04-17 |
Amgen Inc. |
Methods of treatment using specific binding agents of human angiopoietin-2
|
AU2002329570A1
(en)
|
2001-10-12 |
2003-01-30 |
Pfizer Products Inc. |
Method of monitoring neuroprotective treatment
|
GB0124932D0
(en)
|
2001-10-17 |
2001-12-05 |
Glaxo Group Ltd |
Chemical compounds
|
GB0124931D0
(en)
|
2001-10-17 |
2001-12-05 |
Glaxo Group Ltd |
Chemical compounds
|
GB0124941D0
(en)
|
2001-10-17 |
2001-12-05 |
Glaxo Group Ltd |
Chemical compounds
|
GB0124928D0
(en)
|
2001-10-17 |
2001-12-05 |
Glaxo Group Ltd |
Chemical compounds
|
GB0124939D0
(en)
|
2001-10-17 |
2001-12-05 |
Glaxo Group Ltd |
Chemical compounds
|
GB0124936D0
(en)
|
2001-10-17 |
2001-12-05 |
Glaxo Group Ltd |
Chemical compounds
|
GB0124938D0
(en)
|
2001-10-17 |
2001-12-05 |
Glaxo Group Ltd |
Chemical compounds
|
GB0124933D0
(en)
|
2001-10-17 |
2001-12-05 |
Glaxo Group Ltd |
Chemical compounds
|
WO2003039534A1
(en)
|
2001-11-08 |
2003-05-15 |
Merck & Co., Inc. |
Compositions and methods for treating osteoporosis
|
IL161667A0
(en)
|
2001-11-09 |
2004-09-27 |
Scios Inc |
Method and composition to treat cystic fibrosis
|
WO2003048340A2
(en)
|
2001-12-05 |
2003-06-12 |
Vertex Pharmaceuticals Incorporated |
Crystal structure of mitogen-activated protein kinase-activated protein kinase 2 and binding pockets thereof
|
WO2003049742A1
(en)
|
2001-12-11 |
2003-06-19 |
Boehringer Ingelheim Pharmaceuticals, Inc. |
Method for administering birb 796 bs
|
CA2471948A1
(en)
|
2002-01-03 |
2003-07-17 |
Smithkline Beecham Corporation |
Novel pharmaceutical dosage forms and method for producing same
|
CA2472475C
(en)
|
2002-01-15 |
2010-05-18 |
Merck & Co., Inc. |
17-hydroxy-4-aza-androstan-3-ones as androgen receptor modulators
|
DE10203749A1
(de)
|
2002-01-31 |
2003-08-14 |
Boehringer Ingelheim Pharma |
Neue Anticholinergika, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel
|
DE10203741A1
(de)
|
2002-01-31 |
2003-08-14 |
Boehringer Ingelheim Pharma |
Neue Fluorencarbonsäureester, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel
|
DE10203753A1
(de)
|
2002-01-31 |
2003-08-14 |
Boehringer Ingelheim Pharma |
Neue Xanthencarbonsäureester, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel
|
WO2003068223A1
(en)
|
2002-02-11 |
2003-08-21 |
Bayer Corporation |
Aryl ureas with raf kinase and angiogenesis inhibiting activity
|
PT1864975E
(pt)
|
2002-02-12 |
2010-12-27 |
Glaxosmithkline Llc |
Derivados de nicotinamida úteis como inibidores de p38
|
ES2314224T3
(es)
|
2002-03-07 |
2009-03-16 |
F. Hoffmann-La Roche Ag |
Inhibidores pirimidina y piridina biciclicos de p38 quinasa.
|
CN1652786A
(zh)
|
2002-03-13 |
2005-08-10 |
麦克公司 |
作为雄激素受体调节剂的氟代4-氮杂甾体衍生物
|
WO2003079986A2
(en)
|
2002-03-18 |
2003-10-02 |
Bristol-Myers Squibb Company |
Uracil derivatives as inhibitors of tnf-alpha converting enzyme (tace) and matrix metalloproteinases
|
US6900208B2
(en)
|
2002-03-28 |
2005-05-31 |
Bristol Myers Squibb Company |
Pyrrolopyridazine compounds and methods of use thereof for the treatment of proliferative disorders
|
BR0308937A
(pt)
|
2002-04-03 |
2005-01-04 |
Hoffmann La Roche |
Compostos imidazo fundidos
|
IL163737A0
(en)
|
2002-04-05 |
2005-12-18 |
Boehringer Ingelheim Pharma |
Method of treating mucus hypersecretion
|
US20030225089A1
(en)
|
2002-04-10 |
2003-12-04 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
Pharmaceutical compositions based on anticholinergics and p38 kinase inhibitors
|
DE10216339A1
(de)
|
2002-04-13 |
2003-10-23 |
Boehringer Ingelheim Pharma |
Neue Ester hydroxy-substituierter Stickstoffheterocyclen, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel
|
AU2003229689A1
(en)
|
2002-04-15 |
2003-10-27 |
Glaxo Group Limited |
A method of identifying a modudator for a serine/theronine kinase
|
DE60315826T2
(de)
|
2002-04-19 |
2008-05-21 |
Smithkline Beecham Corp. |
Neue verbindungen
|
CA2483164C
(en)
|
2002-04-23 |
2011-06-07 |
Bristol-Myers Squibb Company |
Pyrrolo-triazine aniline compounds useful as kinase inhibitors
|
ES2318122T3
(es)
|
2002-04-23 |
2009-05-01 |
Bristol-Myers Squibb Company |
Compuestos de aril cetona pirrolo-triazina utiles como inhibidores de quinasa.
|
US7388009B2
(en)
|
2002-04-23 |
2008-06-17 |
Bristol-Myers Squibb Company |
Heteroaryl-substituted pyrrolo-triazine compounds useful as kinase inhibitors
|
GB0209891D0
(en)
|
2002-04-30 |
2002-06-05 |
Glaxo Group Ltd |
Novel compounds
|
JP4516839B2
(ja)
|
2002-04-30 |
2010-08-04 |
メルク・シャープ・エンド・ドーム・コーポレイション |
アンドロゲン受容体修飾因子としての4−アザステロイド誘導体
|
WO2003097615A1
(en)
|
2002-05-17 |
2003-11-27 |
Scios, Inc. |
TREATMENT OF FIBROPROLIFERATIVE DISORDERS USING TGF-β INHIBITORS
|
TW200400034A
(en)
|
2002-05-20 |
2004-01-01 |
Bristol Myers Squibb Co |
Pyrazolo-pyrimidine aniline compounds useful as kinase inhibitors
|
WO2003099206A2
(en)
|
2002-05-21 |
2003-12-04 |
Bristol-Myers Squibb Company |
Indole compounds useful as impdh inhibitors
|
AU2003238915B2
(en)
|
2002-06-11 |
2008-02-21 |
Merck & Co., Inc. |
(halo-benzo carbonyl)heterobicyclic p38 kinase inhibiting agents
|
ATE349210T1
(de)
|
2002-07-09 |
2007-01-15 |
Boehringer Ingelheim Pharma |
Pharazeutische zusammensetzungen aus anticholinergica und p38 kinase hemmern zur behandlung von erkrankungen der atemwege
|
CA2494367A1
(en)
|
2002-07-25 |
2004-02-05 |
Scios Inc. |
Methods for improvement of lung function using tgf-.beta. inhibitors
|
GB0217757D0
(en)
|
2002-07-31 |
2002-09-11 |
Glaxo Group Ltd |
Novel compounds
|
CN100432073C
(zh)
|
2002-08-06 |
2008-11-12 |
霍夫曼-拉罗奇有限公司 |
作为p-38map激酶抑制剂的6-烷氧基-吡啶并-嘧啶
|
EP1549621A1
(en)
|
2002-08-08 |
2005-07-06 |
Boehringer Ingelheim Pharmaceuticals Inc. |
Fluorinated phenyl-naphthalenyl-urea compounds as inhibitors of cytokines involved in inflammatory processes
|
ES2274302T3
(es)
|
2002-08-09 |
2007-05-16 |
Eli Lilly And Company |
Benzimidazoles y benzotiazoles como inhibidores de la map quinasa.
|
US20040110755A1
(en)
|
2002-08-13 |
2004-06-10 |
Boehringer Ingelheim Pharmaceuticals, Inc. |
Combination therapy with p38 MAP kinase inhibitors and their pharmaceutical compositions
|
JP2006500365A
(ja)
|
2002-08-14 |
2006-01-05 |
ベーリンガー インゲルハイム ファーマシューティカルズ インコーポレイテッド |
p38MAPキナーゼインヒビターを用いた抗凝固及び線維素溶解療法
|
WO2004019873A2
(en)
|
2002-08-29 |
2004-03-11 |
Scios Inc. |
Methods of promoting osteogenesis
|
US7037923B2
(en)
|
2002-08-30 |
2006-05-02 |
Pfizer, Inc. |
Alkyl-[4-(trifluorophenyl)-oxazol-5-yl]-triazolo-pyridines
|
PA8579601A1
(es)
|
2002-08-30 |
2004-05-07 |
Pfizer Prod Inc |
Compuestos antiinflamatorios de di y trifloruro-triazolo-piridinas
|
US7012143B2
(en)
|
2002-08-30 |
2006-03-14 |
Dombroski Mark A |
Cycloalkyl-[4-(difluorophenyl)-oxazol-5-yl]-triazolo-pyridines
|
US7005523B2
(en)
|
2002-08-30 |
2006-02-28 |
Pfizer Inc. |
Cycloalkyl-[4-(trifluorophenyl)-oxazol-5yl]-triazolo-pyridines
|
BR0313961A
(pt)
|
2002-08-30 |
2005-07-19 |
Pfizer Prod Inc |
Processos e intermediários para preparar triazolo-piridinas
|
US20040092547A1
(en)
|
2002-08-30 |
2004-05-13 |
Pfizer Inc |
Alkyl-[4-(difluorophenyl)-oxazol-5-yl]-triazolo-pyridines
|
US7220763B2
(en)
|
2002-09-03 |
2007-05-22 |
Scios, Inc. |
Indole-type derivatives as inhibitors of p38 kinase
|
CA2497951A1
(en)
|
2002-09-05 |
2004-03-18 |
Scios Inc. |
Treatment of pain by inhibition of p38 map kinase
|
WO2004021979A2
(en)
|
2002-09-06 |
2004-03-18 |
Smithkline Beecham Corporation |
PYRROLO[2, 3-d]PYRIMIDINE-4-YL AND PURIN-6-YL UREA COMPOUNDS
|
US7115644B2
(en)
|
2002-09-13 |
2006-10-03 |
Boehringer Ingelheim Pharmaceuticals Inc. |
Heterocyclic compounds
|
AU2003268156A1
(en)
|
2002-09-17 |
2004-04-08 |
Eli Lilly And Company |
Novel pyrazolopyridine derivatves as pharmaceutical agents
|
WO2004029040A1
(en)
|
2002-09-27 |
2004-04-08 |
Janssen Pharmaceutica N.V. |
3,4-disubstituted pyrroles and their for use in treating inflammatory diseases
|
AU2003282920A1
(en)
|
2002-10-04 |
2004-05-04 |
Bristol-Myers Squibb Company |
Hydantoin derivatives as inhibitors of matrix metalloproteinases and/or tnf-alpha converting enzyme (tace)
|
US20050288299A1
(en)
|
2002-10-09 |
2005-12-29 |
Mavunkel Babu J |
Azaindole derivatives as inhibitors of p38 kinase
|
WO2004032874A2
(en)
|
2002-10-09 |
2004-04-22 |
Scios Inc. |
AZAINDOLE DERIVATIVES AS INHIBITORS OF p38 KINASE
|
WO2004041277A1
(en)
|
2002-11-01 |
2004-05-21 |
Merck & Co., Inc. |
Carbonylamino-benzimidazole derivatives as androgen receptor modulators
|
RU2340618C2
(ru)
|
2002-11-18 |
2008-12-10 |
Ф.Хоффманн-Ля Рош Аг |
Диазинопиримидины и фармацевтическая композиция, содержащая их
|
DE10255040A1
(de)
|
2002-11-26 |
2004-06-03 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
Neue Carbaminsäureester mit anticholinerger Wirksamkeit
|
WO2004053107A2
(en)
|
2002-12-06 |
2004-06-24 |
Scios Inc. |
Methods for treating diabetes
|
WO2004069793A2
(en)
|
2003-01-28 |
2004-08-19 |
Bristol-Myers Squibb Company |
Novel 2-substituted cyclic amines as calcium sensing receptor modulators
|
WO2004072030A2
(en)
|
2003-02-05 |
2004-08-26 |
Bristol-Myers Squibb Company |
Process for preparing pyrrolotriazine kinase inhibitors
|
CA2755297A1
(en)
|
2003-02-10 |
2004-08-26 |
Vertex Pharmaceuticals Incorporated |
Processes for the preparation of n-heteroaryl-n-aryl-amines by reacting an n-aryl carbamic acid ester with a halo-heteroaryl and analogous processes
|
US7205322B2
(en)
|
2003-02-12 |
2007-04-17 |
Bristol-Myers Squibb Company |
Thiazolidine compounds as calcium sensing receptor modulators
|
WO2004072072A1
(en)
|
2003-02-14 |
2004-08-26 |
Pfizer Products Inc. |
Triazolo-pyridines as anti-inflammatory compounds
|
WO2004073628A2
(en)
|
2003-02-14 |
2004-09-02 |
Smithkline Beecham Corporation |
Novel compounds
|
KR101312736B1
(ko)
|
2003-02-27 |
2013-09-27 |
팔라우 파르마 에스에이 |
피라졸로피리딘 유도체
|
CA2517517C
(en)
|
2003-03-03 |
2012-12-18 |
Array Biopharma, Inc. |
P38 inhibitors and methods of use thereof
|
US7135575B2
(en)
|
2003-03-03 |
2006-11-14 |
Array Biopharma, Inc. |
P38 inhibitors and methods of use thereof
|
US7030112B2
(en)
|
2003-03-25 |
2006-04-18 |
Bristol-Myers Squibb Company |
Pyrrolopyridazine compounds and methods of use thereof for the treatment of proliferative disorders
|
GB0308186D0
(en)
|
2003-04-09 |
2003-05-14 |
Smithkline Beecham Corp |
Novel compounds
|
GB0308185D0
(en)
|
2003-04-09 |
2003-05-14 |
Smithkline Beecham Corp |
Novel compounds
|
GB0308201D0
(en)
|
2003-04-09 |
2003-05-14 |
Smithkline Beecham Corp |
Novel compounds
|
MXPA05010975A
(es)
|
2003-04-16 |
2005-11-28 |
Hoffmann La Roche |
Derivados de (6-(fenoxi)-pirido[3,4-d]pirimidin-2-il)-amina como inhibidores de p38 cinasa para el tratamiento de condiciones inflamatorias como artritis reumatoide.
|
KR100812586B1
(ko)
|
2003-04-16 |
2008-03-13 |
에프. 호프만-라 로슈 아게 |
P38 키나아제 저해제로서 유용한 퀴나졸린 화합물
|
ATE482200T1
(de)
|
2003-05-01 |
2010-10-15 |
Bristol Myers Squibb Co |
Als kinaseinhibitoren geeignete arylsubstituierte pyrazolamidverbindungen
|
GB0320244D0
(en)
|
2003-05-06 |
2003-10-01 |
Aventis Pharma Inc |
Pyrazoles as inhibitors of tumour necrosis factor
|
CA2524409C
(en)
|
2003-05-07 |
2011-12-20 |
Merck & Co., Inc. |
Androgen receptor modulators and methods of use thereof
|
EP1633714B1
(en)
|
2003-06-04 |
2008-01-23 |
Pfizer Limited |
2-amino-pyridine derivatives as beta-2 adrenoreceptor agonists
|
ATE517872T1
(de)
|
2003-06-26 |
2011-08-15 |
Novartis Ag |
Fünfgliedrige p38-kinaseinhibitoren auf heterocyclusbasis
|
CA2530182A1
(en)
|
2003-06-30 |
2005-01-20 |
Merck & Co., Inc. |
17-acetamido-4-azasteroid derivatives as androgen receptor modulators
|
WO2005005380A2
(en)
|
2003-06-30 |
2005-01-20 |
Merck & Co., Inc. |
17-acetamido-4-azasteroid derivatives as androgen receptor modulators
|
WO2005009367A2
(en)
|
2003-07-17 |
2005-02-03 |
Ambit Biosciences Corporation |
Treatment of diseases with kinase inhibitors
|
GB0317482D0
(en)
|
2003-07-25 |
2003-08-27 |
Pfizer Ltd |
Nicotinamide derivatives useful as pde4 inhibitors
|
GB0317516D0
(en)
|
2003-07-25 |
2003-08-27 |
Pfizer Ltd |
Nicotinamide derivatives useful as PDE4 inhibitors
|
GB0317484D0
(en)
|
2003-07-25 |
2003-08-27 |
Pfizer Ltd |
Nicotinamide derivatives useful as pde4 inhibitors
|
US20050020587A1
(en)
|
2003-07-25 |
2005-01-27 |
Pfizer Inc |
Nicotinamide derivatives useful as PDE4 inhibitors
|
US7153870B2
(en)
|
2003-07-25 |
2006-12-26 |
Pfizer Inc. |
Nicotinamide derivatives useful as PDE4 inhibitors
|
JP2007507204A
(ja)
|
2003-07-29 |
2007-03-29 |
ブリストル−マイヤーズ スクイブ カンパニー |
サイクリン依存性キナーゼモデュレーションのバイオマーカー
|
GB0318814D0
(en)
|
2003-08-11 |
2003-09-10 |
Smithkline Beecham Corp |
Novel compounds
|
CL2004002050A1
(es)
|
2003-08-13 |
2005-06-03 |
Pharmacia Corp Sa Organizada B |
Compuestos derivados de piridinonas sustituidas; su uso en el tratamiento de afecciones causadas o exacerbadas por actividad p38 map kinasa y/o tnf no regulada, tales como inflamaciones, tumores, sida y otros.
|
BRPI0413757A
(pt)
|
2003-08-22 |
2006-10-31 |
Boehringer Ingelheim Pharma |
métodos para o tratamento de copd e da hipertensão pulmonar
|
US20050053600A1
(en)
|
2003-09-09 |
2005-03-10 |
Lane Thomas E. |
Methods for treating rheumatoid arthritis
|
WO2005025572A1
(en)
|
2003-09-10 |
2005-03-24 |
Merck & Co., Inc. |
17-heterocyclic-4-azasteroid derivatives as androgen receptor modulators
|
WO2005023761A2
(en)
|
2003-09-11 |
2005-03-17 |
Kemia, Inc. |
Cytokine inhibitors
|
US20060019971A1
(en)
|
2003-09-30 |
2006-01-26 |
Higgins Linda S |
Treatment of cardiovascular disease with inhibitors of p38 kinase
|
US7232824B2
(en)
|
2003-09-30 |
2007-06-19 |
Scios, Inc. |
Quinazoline derivatives as medicaments
|
CA2540828A1
(en)
|
2003-09-30 |
2005-04-14 |
Scios Inc. |
Heterocyclic amides and sulfonamides
|
US7419978B2
(en)
|
2003-10-22 |
2008-09-02 |
Bristol-Myers Squibb Company |
Phenyl-aniline substituted bicyclic compounds useful as kinase inhibitors
|
KR100816321B1
(ko)
|
2003-11-13 |
2008-03-24 |
에프. 호프만-라 로슈 아게 |
히드록시알킬 치환 피리도-7-피리미딘-7-온
|
EP1538201A1
(en)
|
2003-12-02 |
2005-06-08 |
F.Hoffmann-La Roche Ag |
Method for the recombinant production and purification of protein kinases
|
GB0329275D0
(en)
|
2003-12-18 |
2004-01-21 |
Merck Sharp & Dohme |
Therapeutic treatment
|
RU2006121487A
(ru)
|
2003-12-18 |
2007-12-27 |
Пфайзер Продактс Инк. (Us) |
СПОСОБЫ ЛЕЧЕНИЯ ОСТРОГО ВОСПАЛЕНИЯ У ЖИВОТНЫХ С ПОМОЩЬЮ ИНГИБИТОРОВ р38 МАР-киназы
|
EP1716121A1
(en)
|
2003-12-18 |
2006-11-02 |
Boehringer Ingelheim Pharmaceuticals Inc. |
Polymorph of birb 796, a p38map kinase inhibitor
|
US20060079461A1
(en)
|
2003-12-24 |
2006-04-13 |
Scios, Inc. |
Treatment of multiple myeloma by inhibition of p38 MAP kinase
|
US20060058296A1
(en)
|
2003-12-24 |
2006-03-16 |
Scios, Inc. |
Treatment of osteolytic lesions associated with multiple myeloma by inhibition of p38 map kinase
|
KR20070007055A
(ko)
|
2003-12-24 |
2007-01-12 |
사이오스 인코퍼레이티드 |
Tgf-베타 억제제를 이용한 악성 신경교종의 치료법
|
US20060052390A1
(en)
|
2003-12-24 |
2006-03-09 |
Scios, Inc. |
Treatment of multiple myeloma by p38 MAP kinase and proteasome inhibition
|
TWI332003B
(en)
|
2004-01-30 |
2010-10-21 |
Lilly Co Eli |
Kinase inhibitors
|
GB0402137D0
(en)
|
2004-01-30 |
2004-03-03 |
Smithkline Beecham Corp |
Novel compounds
|
GB0402138D0
(en)
|
2004-01-30 |
2004-03-03 |
Smithkline Beecham Corp |
Novel compounds
|
GB0402143D0
(en)
|
2004-01-30 |
2004-03-03 |
Smithkline Beecham Corp |
Novel compounds
|
GB0402140D0
(en)
|
2004-01-30 |
2004-03-03 |
Smithkline Beecham Corp |
Novel compounds
|
WO2005075425A2
(en)
|
2004-01-30 |
2005-08-18 |
Merck Patent Gmbh |
Substituted bisarylurea derivatives as kinase inhibitors
|
EP1720862A1
(en)
|
2004-02-03 |
2006-11-15 |
Eli Lilly And Company |
Kinase inhibitors
|
US7652146B2
(en)
|
2004-02-06 |
2010-01-26 |
Bristol-Myers Squibb Company |
Process for preparing 2-aminothiazole-5-carboxamides useful as kinase inhibitors
|
TWI338004B
(en)
|
2004-02-06 |
2011-03-01 |
Bristol Myers Squibb Co |
Process for preparing 2-aminothiazole-5-aromatic carboxamides as kinase inhibitors
|
CA2557398A1
(en)
|
2004-02-26 |
2005-09-09 |
Hans-Peter Buchstaller |
Benzimidazolyl derivatives as kinase inhibitors
|
KR20060114022A
(ko)
|
2004-02-27 |
2006-11-03 |
에프. 호프만-라 로슈 아게 |
인다졸 유도체 및 그들을 함유하는 약학 조성물
|
JP2007523936A
(ja)
|
2004-02-27 |
2007-08-23 |
エフ.ホフマン−ラ ロシュ アーゲー |
ヘテロアリール縮合ピラゾロ誘導体
|
WO2005091891A2
(en)
|
2004-03-11 |
2005-10-06 |
Kythera Biopharmaceuticals, Inc. |
Compositions and methods for preventing and treating skin and hair conditions
|
EP1574501A1
(en)
|
2004-03-11 |
2005-09-14 |
Pfizer Limited |
Quinolinone derivatives, pharmaceutical compositions containing them and their use
|
EP1577292A1
(en)
|
2004-03-17 |
2005-09-21 |
Pfizer Limited |
Phenylaminoethanol derivatives as beta2 receptor agonists
|
EP1577291A1
(en)
|
2004-03-17 |
2005-09-21 |
Pfizer Limited |
Phenylethanolamine derivatives as beta-2 agonists
|
EP1742631A4
(en)
|
2004-04-28 |
2009-11-11 |
Merck & Co Inc |
FLUORATED 4-AZASTEROIDS AS ANDROGEN RECEPTOR MODULATORS
|
CA2566677A1
(en)
|
2004-05-13 |
2005-11-24 |
Intermune, Inc. |
Combination therapy for treating hepatitis virus infection
|
UA87854C2
(en)
|
2004-06-07 |
2009-08-25 |
Мерк Энд Ко., Инк. |
N-(2-benzyl)-2-phenylbutanamides as androgen receptor modulators
|
ES2308523T3
(es)
|
2004-06-23 |
2008-12-01 |
Eli Lilly And Company |
Inhibidores de quinasa.
|
EP1609789A1
(en)
|
2004-06-23 |
2005-12-28 |
Eli Lilly And Company |
Ureido-pyrazole derivatives and their use as kinase inhibitors
|
US7253167B2
(en)
|
2004-06-30 |
2007-08-07 |
Bristol-Myers Squibb Company |
Tricyclic-heteroaryl compounds useful as kinase inhibitors
|
US20060035893A1
(en)
|
2004-08-07 |
2006-02-16 |
Boehringer Ingelheim International Gmbh |
Pharmaceutical compositions for treatment of respiratory and gastrointestinal disorders
|
PE20060421A1
(es)
|
2004-08-12 |
2006-06-01 |
Bristol Myers Squibb Co |
Procedimiento para preparar un compuesto de pirrolotriazina anilina como inhibidores de cinasa
|
SI1778686T1
(sl)
|
2004-08-12 |
2009-02-28 |
Pfizer |
Derivati triazolopiridinilsulfanila kot inhibitorji P38 MAP kinaze
|
CA2576988A1
(en)
|
2004-08-25 |
2006-03-09 |
Merck & Co., Inc. |
Androgen receptor modulators
|
US20070054916A1
(en)
|
2004-10-01 |
2007-03-08 |
Amgen Inc. |
Aryl nitrogen-containing bicyclic compounds and methods of use
|
AR055271A1
(es)
|
2004-10-05 |
2007-08-15 |
Smithkline Beecham Corp |
Compuesto del acido bifenil carboxilico, composicion farmaceutica que lo comprende, su uso para preparar esta ultima y proceso para prepararlo
|
US8003657B2
(en)
|
2004-10-13 |
2011-08-23 |
Merck Patent Gmbh |
Heterocyclic substituted bisarylurea derivatives
|
CN101389335A
(zh)
|
2004-10-18 |
2009-03-18 |
安姆根有限公司 |
噻二唑化合物和使用方法
|
WO2006060108A1
(en)
|
2004-10-29 |
2006-06-08 |
Merck & Co., Inc. |
N-(pyridin-3-yl)-2-phenylbutanamides as androgen receptor modulators
|
US20060258582A1
(en)
|
2004-11-04 |
2006-11-16 |
Scios, Inc. |
Method of treating myelodysplastic syndromes
|
WO2006048266A2
(en)
|
2004-11-04 |
2006-05-11 |
Roche Diagnostics Gmbh |
Gene expression profiling of leukemias with mll gene rearrangements
|
GB0425057D0
(en)
|
2004-11-12 |
2004-12-15 |
Pfizer Ltd |
L-tartrate salt of N-1-adamantyl-2-{3-[(2R)-2-hydroxy-2-[4-hydroxy-3-(hydroxymethyl)phenyl]eth yl}amino)propyl]phenyl}acetamide
|
WO2006051373A1
(en)
|
2004-11-12 |
2006-05-18 |
Pfizer Limited |
Compounds for the treatment of diseases
|
CN101056842A
(zh)
|
2004-11-16 |
2007-10-17 |
默克公司 |
治疗中风的(2r)-2-丙基辛酸前药
|
US20080139614A1
(en)
|
2004-11-23 |
2008-06-12 |
Seabrook Guy R |
Treatment Of Stroke With Histamine H3 Inverse Agonists Or Histamine H3 Antagonists
|
US20060111416A1
(en)
|
2004-11-24 |
2006-05-25 |
Lane Charlotte A L |
Octahydropyrrolo[3,4-C]pyrrole derivatives
|
US20070224662A1
(en)
|
2004-12-17 |
2007-09-27 |
Jun Luo |
Post-translational modification of proteins in cell-free expression systems
|
PE20060777A1
(es)
|
2004-12-24 |
2006-10-06 |
Boehringer Ingelheim Int |
Derivados de indolinona para el tratamiento o la prevencion de enfermedades fibroticas
|
PE20061155A1
(es)
|
2004-12-24 |
2006-12-16 |
Boehringer Ingelheim Int |
Derivados de indolinona como agentes para el tratamiento o la prevencion de enfermedades fibroticas
|
US20060154939A1
(en)
|
2004-12-24 |
2006-07-13 |
Boehringer Ingelheim International Gmbh |
Medicaments for the Treatment or Prevention of Fibrotic Diseases
|
CN101080404B
(zh)
|
2004-12-28 |
2011-06-08 |
Aska制药株式会社 |
嘧啶基异噁唑衍生物
|
US20060178388A1
(en)
|
2005-02-04 |
2006-08-10 |
Wrobleski Stephen T |
Phenyl-substituted pyrimidine compounds useful as kinase inhibitors
|
ES2351308T3
(es)
|
2005-02-28 |
2011-02-02 |
Merckle Gmbh |
Derivados de imidazol 2-sulfinil- y 2-sulfonil-sustituidos y su uso como inhibidores de citocina.
|
US7759337B2
(en)
|
2005-03-03 |
2010-07-20 |
Amgen Inc. |
Phthalazine compounds and methods of use
|
AR053450A1
(es)
|
2005-03-25 |
2007-05-09 |
Glaxo Group Ltd |
Derivados de 3,4-dihidro-pirimido(4,5-d)pirimidin-2-(1h)-ona 1,5,7 trisustituidos como inhibidores de la quinasa p38
|
AR053346A1
(es)
|
2005-03-25 |
2007-05-02 |
Glaxo Group Ltd |
Compuesto derivado de 8h -pirido (2,3-d) pirimidin -7 ona 2,4,8- trisustituida composicion farmaceutica y uso para preparar una composicion para tratamiento y profilxis de una enfermedad mediada por la quinasa csbp/ rk/p38
|
WO2006110298A2
(en)
|
2005-03-25 |
2006-10-19 |
Glaxo Group Limited |
8-alkyl/aryl-4-aryl-2-n- (alkylamino)-n'-substituted-n'-cyanoguanidino-8h-pyrido[2,3-d]pyrimidin-7-one compounds and use thereof
|
US20060235020A1
(en)
|
2005-04-18 |
2006-10-19 |
Soojin Kim |
Process for preparing salts of 4-[[5-[(cyclopropylamino)carbonyl]-2-methylphenyl]amino]-5-methyl-N-propylpyrrolo[2,1-f][1,2,4]triazine-6-carboxamide and novel stable forms produced therein
|
WO2006122230A1
(en)
|
2005-05-11 |
2006-11-16 |
Array Biopharma Inc. |
P38 inhibitors and methods of use thereof
|
JP2008545696A
(ja)
|
2005-05-23 |
2008-12-18 |
スミスクライン・ビーチャム・コーポレイション |
肥満の処置のためのp38markの阻害
|
GB0512429D0
(en)
|
2005-06-17 |
2005-07-27 |
Smithkline Beecham Corp |
Novel compound
|
US20070032506A1
(en)
|
2005-07-02 |
2007-02-08 |
Peter Giannousis |
Crystalline forms of (2r-trans)-6-chloro-5[[4-[(4-fluorophenyl)methyl]-2,5-dimethyl-1-piperazinyl]carbonyl]-n,n, 1-trimethyl-alpha-oxo-1h-indole-3-acetamide monohydrochloride
|
US7473784B2
(en)
|
2005-08-01 |
2009-01-06 |
Bristol-Myers Squibb Company |
Benzothiazole and azabenzothiazole compounds useful as kinase inhibitors
|
CN101233109A
(zh)
|
2005-08-02 |
2008-07-30 |
默克公司 |
用作雄激素受体调节剂的n-(吡啶-4-基)-2-苯基丁酰胺
|
CN102627640A
(zh)
|
2005-08-12 |
2012-08-08 |
默沙东公司 |
可用作p38激酶抑制剂的杂二环化合物
|
US20070049592A1
(en)
|
2005-08-22 |
2007-03-01 |
Geuns-Meyer Stephanie D |
Bis-aryl urea compounds and methods of use
|
CA2620254A1
(en)
|
2005-08-25 |
2007-03-01 |
F. Hoffmann-La Roche Ag |
P38 map kinase inhibitors and methods for using the same
|
BRPI0615442A2
(pt)
|
2005-08-25 |
2011-05-17 |
Hoffmann La Roche |
inibidores de p38 map cinase e métodos para uso dos mesmos
|
AU2006283945A1
(en)
|
2005-08-25 |
2007-03-01 |
F. Hoffmann-La Roche Ag |
P38 MAP kinase inhibitors and methods for using the same
|
KR20080031460A
(ko)
|
2005-08-25 |
2008-04-08 |
에프. 호프만-라 로슈 아게 |
P38 map 키나아제 저해제 및 이의 사용 방법
|
MX2008002383A
(es)
|
2005-08-25 |
2008-03-18 |
Hoffmann La Roche |
Pirazol fusionado como inhibidores de proteinas cinasas activadas por mitogenos p38.
|
CN101268079B
(zh)
|
2005-09-01 |
2011-09-14 |
安斯泰来制药有限公司 |
用于治疗疼痛的哒嗪酮衍生物
|
AP1983A
(en)
|
2005-09-21 |
2009-03-24 |
Pfizer Ltd |
Carboxamide derivatives as muscarinic receptor antagonists
|
AU2006294835B2
(en)
|
2005-09-26 |
2011-05-26 |
Merck Sharp & Dohme Corp. |
N-(4-oxo-3,4-dihydroquinazolin-2-yl)butanamides as androgen receptor modulators
|
WO2007045989A1
(en)
|
2005-10-20 |
2007-04-26 |
Pfizer Limited |
Pyridyl derivatives useful as h3 ligands
|
DOP2006000234A
(es)
|
2005-10-28 |
2007-05-31 |
Lilly Co Eli |
Inhibidores de cinasa
|
PE20070640A1
(es)
|
2005-10-28 |
2007-08-10 |
Lilly Co Eli |
Compuestos derivados de pirazol-isoquinolina urea como inhibidores de la cinasa p38
|
WO2007056016A2
(en)
|
2005-11-02 |
2007-05-18 |
Kemia, Inc. |
Bisamide cytokine inhibitors
|
WO2007052124A1
(en)
|
2005-11-04 |
2007-05-10 |
Pfizer Limited |
Tetrahydronaphthyridine derivative
|
BRPI0618379A2
(pt)
|
2005-11-08 |
2011-08-30 |
Ranbaxy Lab Ltd |
processo para preparação do hemi-sal de cálcio do ácido (3r,5r) -7-[2-(4-fluorofenil)-5-isopropil-3-fenil-4-[(4-hidroxime tilfenilamino) carbonil]-pirrol-1-il] -3, 5-diidroxi heptanóico
|
PE20100743A1
(es)
|
2005-11-15 |
2010-11-25 |
Glaxo Group Ltd |
Nuevos procedimientos y formulaciones
|
NL2000323C2
(nl)
|
2005-12-20 |
2007-11-20 |
Pfizer Ltd |
Pyrimidine-derivaten.
|
WO2007075896A2
(en)
|
2005-12-22 |
2007-07-05 |
Kemia, Inc. |
Heterocyclic cytokine inhibitors
|
CA2636077C
(en)
|
2006-01-18 |
2012-01-03 |
Amgen Inc. |
Thiazole compounds as protein kinase b (pkb) inhibitors
|
RU2442777C2
(ru)
|
2006-01-31 |
2012-02-20 |
Эррэй Биофарма Инк. |
Ингибиторы киназ и способы их применения
|
CA2642209A1
(en)
|
2006-02-09 |
2007-08-16 |
Pfizer Limited |
Triazolopyridine compounds
|
JP2009526039A
(ja)
|
2006-02-10 |
2009-07-16 |
ファイザー・プロダクツ・インク |
ピリジノンピラゾール尿素およびピリミジノンピラゾール尿素誘導体
|
GB0603684D0
(en)
|
2006-02-23 |
2006-04-05 |
Novartis Ag |
Organic compounds
|
WO2007103839A2
(en)
|
2006-03-07 |
2007-09-13 |
Bristol-Myers Squibb Company |
Pyrrolotriazine aniline prodrug compounds useful as kinase inhibitors
|
US20070225339A1
(en)
|
2006-03-07 |
2007-09-27 |
Ramon Mohanlal |
Compositions and methods for treating rheumatoid arthritis
|
JP2009530364A
(ja)
|
2006-03-20 |
2009-08-27 |
ファイザー・リミテッド |
アミン誘導体
|
US8026233B2
(en)
|
2006-03-29 |
2011-09-27 |
Array Biopharma Inc. |
P38 inhibitors and methods of use thereof
|
WO2007115670A1
(en)
|
2006-04-12 |
2007-10-18 |
Merck Patent Gmbh |
N-oxides of heterocyclic substituted bisarylureas for treating kinase-mediated diseases
|
CA2649543A1
(en)
|
2006-04-21 |
2007-11-01 |
Amgen Inc. |
Thieno-[2,3-d]pyrimidine and thieno-pyridazine compounds and methods of use
|
EP2035005A4
(en)
|
2006-06-09 |
2011-07-06 |
Kemia Inc |
THERAPY BASED ON CYTOKINE INHIBITORS
|
EP2032142A4
(en)
|
2006-06-16 |
2010-07-21 |
Glaxo Group Ltd |
NOVEL CONNECTIONS
|
US20100144755A1
(en)
|
2006-06-16 |
2010-06-10 |
Glaxo Group Limited |
Novel Compounds
|
GB0612026D0
(en)
|
2006-06-16 |
2006-07-26 |
Smithkline Beecham Corp |
New use
|
EP2031965A4
(en)
|
2006-06-16 |
2010-06-30 |
Glaxo Group Ltd |
NEW COMPOUNDS
|
KR20090031721A
(ko)
|
2006-06-28 |
2009-03-27 |
아스카 세이야쿠 가부시키가이샤 |
염증성 장 질환의 처치제
|
ES2396251T3
(es)
|
2006-06-28 |
2013-02-20 |
Aska Pharmaceutical Co., Ltd. |
Derivado de piridilisoxazol
|
AU2007275696B2
(en)
|
2006-07-17 |
2011-11-10 |
Amgen Inc. |
Quinazoline and pyridopyrimidine derivatives as p38 kinase inhibitors
|
WO2008013823A2
(en)
|
2006-07-26 |
2008-01-31 |
Scios Inc. |
Co-crystals of (2r-trans)-6-chloro-5-[[4-[(4-fluorophenyl)methyl]-2,5-dimethyl-1-piperazinyl]carbonyl]-n,n,1-trimethyl-alpha-oxo-1h-indole-3-acetamide
|
WO2008105808A2
(en)
|
2006-07-28 |
2008-09-04 |
Onconova Therapeutics, Inc. |
FORMULATIONS OF RADIOPROTECTIVE α, β UNSATURATED ARYL SULFONES
|
PE20080906A1
(es)
|
2006-08-17 |
2008-07-05 |
Kemia Inc |
Derivados heteroarilo como inhibidores de citocina
|
WO2008024391A1
(en)
|
2006-08-22 |
2008-02-28 |
Scios Inc. |
Pharmaceutical formulations of an indole-type derivative and related methods of use
|
KR20090050104A
(ko)
|
2006-10-04 |
2009-05-19 |
화이자 리미티드 |
아드레날린성 효능제 및 무스카린성 길항제로서 술폰아미드 유도체
|
ATE542818T1
(de)
|
2006-10-11 |
2012-02-15 |
Amgen Inc |
Imidazo- und triazolopyridinverbindungen und verfahren zu deren anwendung
|
EP2083624A4
(en)
|
2006-10-18 |
2010-06-16 |
Merck Sharp & Dohme |
2-HYDROXY-2-PHENYL / THIOPHENYLPROPIONAMIDE AS ANDROGEN RECEPTOR MODULATORS
|
CA2667543A1
(en)
|
2006-10-26 |
2008-05-02 |
Boehringer Ingelheim International Gmbh |
New pharmaceutical combinations for treatment of respiratory and gastrointestinal disorders
|
US7943617B2
(en)
|
2006-11-27 |
2011-05-17 |
Bristol-Myers Squibb Company |
Heterobicyclic compounds useful as kinase inhibitors
|
WO2008071665A1
(en)
|
2006-12-12 |
2008-06-19 |
Smithkline Beecham Corporation |
A nicotinamide derivative useful as p38 kinase inhibitor
|
WO2008071664A1
(en)
|
2006-12-12 |
2008-06-19 |
Smithkline Beecham Corporation |
Nicotinamide derivative used as a p38 kinase inhibitor
|
WO2008072079A2
(en)
|
2006-12-13 |
2008-06-19 |
Pfizer Products Inc. |
Processes for the preparation of 3-(4-(2,4-difluorobenzyloxy)-3-bromo-6-methyl-2-oxopyridin-1(2h)-yl)-n,4-dimethylbenzamide
|
RU2009126633A
(ru)
|
2006-12-13 |
2011-01-20 |
Джилид Сайэнс, Инк. (US) |
Монофосфатные соединения, способ их получения, аэрозольный препарат (варианты) и способ профилактики и/или лечения бронхостеноза посредством указанных соединений
|
WO2008074676A1
(en)
|
2006-12-19 |
2008-06-26 |
F. Hoffmann-La Roche Ag |
Pyrazolo [3, 4 -d] pyrimidine p38 map kinase inhibitors
|
WO2008079857A1
(en)
|
2006-12-20 |
2008-07-03 |
Bristol-Myers Squibb Company |
Crystalline forms of aryl-substituted pyrazole-amide compounds
|
WO2008089034A2
(en)
|
2007-01-11 |
2008-07-24 |
Kemia, Inc. |
Cytokine inhibitors
|
US8063094B2
(en)
|
2007-02-08 |
2011-11-22 |
Boehringer Ingelheim International Gmbh |
Anti-cytokine heterocyclic compounds
|
CN101610754A
(zh)
|
2007-02-16 |
2009-12-23 |
Aska制药株式会社 |
含有微粒油性混悬液的药物组合物
|
US20100015218A1
(en)
|
2007-02-16 |
2010-01-21 |
Vasant Jadhav |
Compositions and methods for potentiated activity of biologically active molecules
|
WO2008104473A2
(en)
|
2007-02-28 |
2008-09-04 |
F. Hoffmann-La Roche Ag |
Pyrazolopyriidine derivatives and their use as kinase inhibitors
|
US8263583B2
(en)
|
2007-03-16 |
2012-09-11 |
Pfizer Limited |
Hydrochloride salt of 5-[3-(3-hydroxyphenoxy)azetidin-1-yl]-5-methyl-2,2-diphenylhexanamide
|
WO2008136948A1
(en)
|
2007-05-07 |
2008-11-13 |
Amgen Inc. |
Pyrazolo-pyridinone and pyrazolo-pyrazinone compounds as p38 modulators, process for their preparation, and their pharmaceutical use
|
EP2152704A1
(en)
|
2007-05-07 |
2010-02-17 |
Amgen, Inc |
Pyrazolo-pyridinone compounds, process for their preparation, and their pharmaceutical use
|
EP2173728A2
(en)
|
2007-07-17 |
2010-04-14 |
Amgen Inc. |
Heterocyclic modulators of pkb
|
AU2008276512A1
(en)
|
2007-07-17 |
2009-01-22 |
Amgen Inc. |
Thiadiazole modulators of PKB
|
US7943658B2
(en)
|
2007-07-23 |
2011-05-17 |
Bristol-Myers Squibb Company |
Indole indane amide compounds useful as CB2 agonists and method
|
US8202899B2
(en)
|
2007-07-25 |
2012-06-19 |
Array Biopharma Inc. |
Pyrazole urea derivatives used as kinase inhibitors
|
WO2009034432A2
(en)
|
2007-09-14 |
2009-03-19 |
Pfizer Limited |
Novel compounds active as muscarinic receptor antagonists
|
US8314131B2
(en)
|
2007-09-21 |
2012-11-20 |
Amgen Inc. |
Triazole fused heteroaryl compounds and methods of use thereof
|
BRPI0820447A2
(pt)
|
2007-11-30 |
2015-05-26 |
Pfizer Ltd |
Agonistas do receptor de glicocorticóides
|
GB0724258D0
(en)
|
2007-12-12 |
2008-01-30 |
Glaxo Group Ltd |
Novel combinations
|
WO2009074518A1
(en)
|
2007-12-12 |
2009-06-18 |
Glaxo Group Limited |
Combinations of prolinamide p2x7 modulators with further therapeutic agents
|
WO2009078992A1
(en)
|
2007-12-17 |
2009-06-25 |
Amgen Inc. |
Linear tricyclic compounds as p38 kinase inhibitors
|
WO2009094556A2
(en)
|
2008-01-25 |
2009-07-30 |
Bristol-Myers Squibb Pharma Company |
Identification of predictive markers of response to dasatinib in human colon cancer
|
JP2011512209A
(ja)
|
2008-02-20 |
2011-04-21 |
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
粉末吸入器
|
WO2009117156A1
(en)
|
2008-03-21 |
2009-09-24 |
Amgen Inc. |
Pyrazolo-pyrazinone compounds and methods of use thereof
|
JP2009263234A
(ja)
|
2008-04-21 |
2009-11-12 |
Ranbaxy Lab Ltd |
ホスホジエステラーゼタイプiv阻害剤の組成物
|
AR072008A1
(es)
|
2008-06-13 |
2010-07-28 |
Merck & Co Inc |
Compuestos heterobiciclicos como agentes de inhibicion de quinasa p38
|
CN102131806A
(zh)
|
2008-06-20 |
2011-07-20 |
百时美施贵宝公司 |
用作激酶抑制剂的***并吡啶化合物
|
WO2009155388A1
(en)
|
2008-06-20 |
2009-12-23 |
Bristol-Myers Squibb Company |
Imidazopyridine and imidazopyrazine compounds useful as kinase inhibitors
|
WO2009158446A2
(en)
|
2008-06-25 |
2009-12-30 |
Bristol-Myers Squibb Company |
Crystalline forms of ((((4-((5-(cyclopropylcarbamoyl)-2-methylphenyl)amino)-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yl)carbonyl)(propyl)carbamoyl)oxy)methyl (4-(phosphonooxy)phenyl)acetate, method of preparation and use thereof
|
WO2009158450A1
(en)
|
2008-06-25 |
2009-12-30 |
Bristol-Myers Squibb Company |
Crystalline forms of ((((4-((5-(cyclopropylcarbamoyl)-2-methylphenyl)amino)-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yl)carbonyl)(propyl)carbamoyl)oxy)methyl (4-(phosphonooxy)phenyl)acetate, preparation and use thereof
|
US8263623B2
(en)
|
2008-07-11 |
2012-09-11 |
Pfizer Inc. |
Triazol derivatives useful for the treatment of diseases
|
JP2011528346A
(ja)
|
2008-07-15 |
2011-11-17 |
ファイザー・リミテッド |
ムスカリン受容体アンタゴニストとして活性のある新規化合物
|
WO2010007561A1
(en)
|
2008-07-15 |
2010-01-21 |
Pfizer Limited |
Novel compounds active as muscarinic receptor antagonists
|
US8455495B2
(en)
|
2008-08-29 |
2013-06-04 |
Amgen Inc. |
Pyridazino-pyridinone compounds and methods of use
|
EP2334673A1
(en)
|
2008-08-29 |
2011-06-22 |
Amgen Inc. |
PYRIDO[3,2-d]PYRIDAZINE-2(1H)-ONE COMPOUNDS AS P38 MODULATORS AND METHODS OF USE THEREOF
|
WO2010038428A1
(ja)
|
2008-09-30 |
2010-04-08 |
武田薬品工業株式会社 |
タキサン系抗がん剤の置き換え薬
|
EP2206534A1
(de)
|
2008-10-09 |
2010-07-14 |
c-a-i-r biosciences GmbH |
Dibenzocycloheptanonderivate und pharmazeutische Mittel, welche diese Verbindungen enthalten
|
WO2010042646A1
(en)
|
2008-10-10 |
2010-04-15 |
Amgen Inc. |
Aza- and diaza-phthalazine compounds as p38 map kinase modulators and methods of use thereof
|
US8497269B2
(en)
|
2008-10-10 |
2013-07-30 |
Amgen Inc. |
Phthalazine compounds as p38 map kinase modulators and methods of use thereof
|
WO2010083246A1
(en)
|
2009-01-15 |
2010-07-22 |
Amgen Inc. |
Fluoroisoquinoline substituted thiazole compounds and methods of use
|
US20120129820A1
(en)
|
2009-02-09 |
2012-05-24 |
Boehringer Ingelheim International Gmbh |
New pharmaceutical compositions for treatment of respiratory and gastrointestinal disorders
|
MX2011008499A
(es)
|
2009-02-13 |
2011-09-06 |
Vertex Pharma |
Formas solidas de 2-(2,4-difluorofenil)-6-(1-(2,6-difluorofenil)ur eido)nicotinamida.
|
EP2396302A2
(en)
|
2009-02-13 |
2011-12-21 |
Vertex Pharmceuticals Incorporated |
Processes for producing phenyl-6-(1-(phenyl)ureido)nicotinamides)
|
WO2010094956A1
(en)
|
2009-02-17 |
2010-08-26 |
Pulmagen Therapeutics (Inflammation) Limited. |
Triazolopyridine derivatives as p38 map kinase inhibitors
|
GB0902648D0
(en)
|
2009-02-17 |
2009-04-01 |
Argenta Discovery Ltd |
Pharmaceutical compounds and compositions
|
WO2010120963A1
(en)
|
2009-04-16 |
2010-10-21 |
Bristol-Myers Squibb Company |
Tablet formulation for p38 inhibitor and method
|
AU2010245072B2
(en)
|
2009-05-05 |
2013-11-28 |
Merck Sharp & Dohme Corp. |
p38 kinase inhibiting agents
|
US20120157500A1
(en)
|
2009-08-24 |
2012-06-21 |
Weikang Tao |
Jak inhibition blocks rna interference associated toxicities
|
BR112012009257A2
(pt)
|
2009-10-22 |
2016-11-22 |
Genentech Inc |
modulação de degeneração de axônio.
|
WO2011063076A1
(en)
|
2009-11-19 |
2011-05-26 |
Itherx Pharmaceuticals, Inc. |
Methods of treating hepatitis c virus with oxoacetamide compounds
|
WO2011083387A1
(en)
|
2010-01-07 |
2011-07-14 |
Pfizer Limited |
Hydrochloride salt of biphenyl-2-yl-carbamic acid 1-{9-[(3-fluoro-4-hydroxy-benzoyl)-methyl-amino]-nonyl}-piperidin-4-yl ester
|
US9044427B2
(en)
|
2010-03-24 |
2015-06-02 |
Onconova Therapeutics, Inc |
Compositions and methods for prevention and treatment of wounds
|
CA2792913C
(en)
|
2010-03-26 |
2020-01-21 |
Onconova Therapeutics, Inc. |
Improved stable aqueous formulation of (e)-4-carboxystyryl-4-chlorobenzyl sulfone
|
GB201009731D0
(en)
|
2010-06-10 |
2010-07-21 |
Pulmagen Therapeutics Inflamma |
Kinase inhibitors
|
US8791113B2
(en)
|
2010-06-28 |
2014-07-29 |
Merck Patent Gmbh |
2,4-diaryl-substituted [1,8] naphthyridines as kinase inhibitors for use against cancer
|
BR112012033658A2
(pt)
|
2010-07-05 |
2016-11-29 |
Merck Patent Gmbh |
derivados bipiridílicos úteis para o tratamento de doenças induzidas por quinases
|
WO2012031057A1
(en)
|
2010-09-01 |
2012-03-08 |
Bristol-Myers Squibb Company |
Bms- 582949 for the treatment of resistant rheumatic disease
|
KR20130142144A
(ko)
|
2010-11-29 |
2013-12-27 |
제넨테크, 인크. |
신경변성 질환 또는 장애의 검출 방법
|
AR083868A1
(es)
|
2010-12-03 |
2013-03-27 |
Lilly Co Eli |
Compuestos de oxazol[5,4-b]piridin-5-ilo
|
KR20140022829A
(ko)
|
2011-03-09 |
2014-02-25 |
메르크 파텐트 게엠베하 |
피리도 [2, 3 - b] 피라진 유도체 및 그 치료적 용도
|
US8697627B2
(en)
|
2011-05-09 |
2014-04-15 |
Eip Pharma, Llc |
Compositions and methods for treating alzheimer's disease
|
WO2012168359A1
(en)
|
2011-06-10 |
2012-12-13 |
Chiesi Farmaceutici S.P.A. |
Compounds having muscarinic receptor antagonist and beta2 adrenergic receptor agonist activity
|
WO2013007708A1
(en)
|
2011-07-08 |
2013-01-17 |
Helmholtz-Zentrum für Infektionsforschung GmbH |
Medicament for treatment of liver cancer
|
DK2780011T3
(en)
|
2011-11-11 |
2018-05-28 |
Lilly Co Eli |
COMBINATION THERAPY AGAINST OVARI CANCER
|
WO2013086002A1
(en)
|
2011-12-05 |
2013-06-13 |
Cellworks Research India Private Limited |
Compositions, process of preparation of said compositions and method of treating cancer
|
DK2788349T3
(en)
|
2011-12-09 |
2017-01-30 |
Chiesi Farm Spa |
kinase inhibitors
|
SG11201402986RA
(en)
|
2011-12-09 |
2014-12-30 |
Chiesi Farma Spa |
Kinase inhibitors
|
KR20140103925A
(ko)
|
2011-12-09 |
2014-08-27 |
키에시 파르마슈티시 엣스. 피. 에이. |
4-히드록시-1,2,3,4-테트라히드로나프탈렌-1-일 우레아 및 호흡기 질환의 치료에서의 이들의 용도
|
CN104736569A
(zh)
|
2012-01-12 |
2015-06-24 |
耶鲁大学 |
通过e3泛素连接酶增强靶蛋白质及其他多肽降解的化合物和方法
|
PL2819998T3
(pl)
|
2012-03-01 |
2022-06-27 |
Array Biopharma Inc. |
Krystaliczne postacie chlorowodorku 1-(3-tert-butylo-1-p-tolilo-1h-pirazol-5-ilo)-3-(5-fluoro-2-(1-(2-hydroksyetylo)-1h-indazol-5-iloksy)benzylo)mocznika
|
CA2866108C
(en)
|
2012-03-20 |
2017-03-07 |
Novartis Ag |
Use of a pyrazole derivative in the treatment of acute exacerbations of chronic obstructive pulmonary disease
|
EP2852584B1
(en)
|
2012-05-22 |
2018-02-28 |
F. Hoffmann-La Roche AG |
Substituted dipyridylamines and uses thereof
|
KR20150036631A
(ko)
|
2012-07-17 |
2015-04-07 |
글락소스미스클라인 엘엘씨 |
급성 관상동맥 증후군의 치료에서의 니코틴아미드 유도체
|
GB201214750D0
(en)
|
2012-08-17 |
2012-10-03 |
Respivert Ltd |
Compounds
|
GB201215357D0
(en)
|
2012-08-29 |
2012-10-10 |
Respivert Ltd |
Compounds
|
WO2014033449A1
(en)
|
2012-08-29 |
2014-03-06 |
Respivert Limited |
Kinase inhibitors
|
WO2014033447A2
(en)
|
2012-08-29 |
2014-03-06 |
Respivert Limited |
Kinase inhibitors
|
WO2014033446A1
(en)
|
2012-08-29 |
2014-03-06 |
Respivert Limited |
Kinase inhibitors
|
US9155747B2
(en)
|
2012-09-13 |
2015-10-13 |
Chiesi Farmaceutici S.P.A. |
Isoxazolidine derivatives
|
WO2014076484A1
(en)
|
2012-11-16 |
2014-05-22 |
Respivert Limited |
Kinase inhibitors
|
CA2891634A1
(en)
|
2012-11-30 |
2014-06-05 |
F. Hoffmann-La Roche Ag |
Inhibitors of bruton's tyrosine kinase
|
US9370527B2
(en)
|
2012-12-28 |
2016-06-21 |
The Regents Of The University Of Michigan |
Amelioration of intestinal fibrosis and treatment of Crohn's disease
|
US9790206B2
(en)
|
2013-02-27 |
2017-10-17 |
Array Biopharma Inc. |
Intermediates for use in the preparation of indazole derivatives and processes for the preparation thereof
|
EP2970190A1
(en)
|
2013-03-14 |
2016-01-20 |
Respivert Limited |
Kinase inhibitors
|
GB201305714D0
(en)
|
2013-03-28 |
2013-05-15 |
Ucl Business Plc |
Method
|
MX363950B
(es)
|
2013-04-02 |
2019-04-08 |
Topivert Pharma Ltd |
Derivados de urea utiles como inhibidores de quinasa.
|
WO2014181213A1
(en)
|
2013-05-10 |
2014-11-13 |
Pfizer Inc. |
Crystalline form of (sa)-(-)-3-(3-bromo-4-((2,4-difluorobenzyl)oxy)-6-methyl-2-oxopyridin-1 (2h)-yl)-n,4-dimethylbenzamide
|
BR112015029504A2
(pt)
|
2013-06-06 |
2017-07-25 |
Chiesi Farm Spa |
inibidores quinase
|
CN105377847A
(zh)
|
2013-06-06 |
2016-03-02 |
奇斯药制品公司 |
激酶抑制剂
|
KR20160015221A
(ko)
|
2013-06-06 |
2016-02-12 |
키에시 파르마슈티시 엣스. 피. 에이. |
키나아제 억제제
|
US9707219B2
(en)
|
2013-07-10 |
2017-07-18 |
Glaxosmithkline Intellectual Property (No.2) Limited |
Losmapimod for use in treating glomerular disease
|
US9918989B2
(en)
|
2013-07-12 |
2018-03-20 |
The Regents Of The University Of California |
Combination therapies for malaria
|
US9814728B2
(en)
*
|
2013-09-20 |
2017-11-14 |
Saint Louis University |
Inhibition of DUX4 expression using bromodomain and extra-terminal domain protein inhibitors (BETi)
|
EP3069732B1
(en)
*
|
2013-11-14 |
2023-07-12 |
The Doshisha |
Drug for treating corneal endothelium by promoting cell proliferation or inhibiting cell damage
|
MX2016008110A
(es)
|
2013-12-20 |
2016-08-19 |
Hoffmann La Roche |
Derivados de pirazol como inhibidores de la cinasa de cremallera de leucina dual (dlk) y usos de los mismos.
|
WO2015092423A1
(en)
|
2013-12-20 |
2015-06-25 |
Respivert Limited |
Urea derivatives useful as kinase inhibitors
|
CN110522731B
(zh)
|
2014-02-14 |
2022-08-02 |
瑞斯比维特有限公司 |
作为抗炎化合物的芳族杂环化合物
|
CA2940028A1
(en)
|
2014-02-19 |
2015-08-27 |
H. Lundbeck A/S |
2-amino-3,5,5-trifluoro-3,4,5,6-tetrahydropyridines as bace1 inhibitors for treatment of alzheimer's disease
|
WO2015191986A1
(en)
|
2014-06-13 |
2015-12-17 |
Genentech, Inc. |
Methods of treating and preventing cancer drug resistance
|
JP2017517558A
(ja)
|
2014-06-13 |
2017-06-29 |
ジェネンテック, インコーポレイテッド |
癌薬剤耐性の治療方法及び防止方法
|
EP3166610B1
(en)
|
2014-07-09 |
2022-11-02 |
Eip Pharma, LLC |
Methods for treating neurologic disorders
|
WO2016051186A1
(en)
|
2014-10-01 |
2016-04-07 |
Respivert Limited |
N-phenyl-3-quinazolin-6-yl-benzamide derivatives as p38 kinase inhibitors
|
MA40775A
(fr)
|
2014-10-01 |
2017-08-08 |
Respivert Ltd |
Dérivé d'acide 4-(4-(4-phényluréido-naphtalén -1-yl) oxy-pyridin-2-yl) amino-benzoïque utilisé en tant qu'inhibiteur de la kinase p38
|
WO2016049677A1
(en)
|
2014-10-03 |
2016-04-07 |
The Walter And Eliza Hall Institute Of Medical Research |
Method of treating cancer
|
WO2016066687A1
(en)
|
2014-10-30 |
2016-05-06 |
Glaxosmithkline Intellectual Property (No.2) Limited |
Losmapimod for treating copd
|
WO2016114655A1
(en)
*
|
2015-01-12 |
2016-07-21 |
Ry Pharma B.V. |
Treating neuromuscular or neurologic disease through reducing gabaergic and/or glycinergic inhibitory neurotransmitter overstimulation
|
WO2016115490A1
(en)
|
2015-01-16 |
2016-07-21 |
Ionis Pharmaceuticals, Inc. |
Compounds and methods for modulation of dux4
|
CA2975750C
(en)
*
|
2015-02-06 |
2023-06-13 |
Association Institut De Myologie |
Treatment of facioscapulohumeral dystrophy
|
TWI703138B
(zh)
|
2015-02-12 |
2020-09-01 |
義大利商吉斯藥品公司 |
具有蕈毒鹼受體拮抗劑及β2腎上腺素受體促效劑活性之化合物
|
CN107406462B
(zh)
|
2015-03-09 |
2020-11-10 |
豪夫迈·罗氏有限公司 |
三环dlk抑制剂及其用途
|
WO2016154329A2
(en)
*
|
2015-03-24 |
2016-09-29 |
The Trustees Of The University Of Pennsylvania |
P38 map kinase inhibitors for treating friedreich's ataxia
|
JP2016193870A
(ja)
|
2015-04-01 |
2016-11-17 |
国立大学法人広島大学 |
慢性骨髄性白血病治療剤
|
US9968604B2
(en)
|
2015-04-16 |
2018-05-15 |
Chiesi Farmaceutici S.P.A. |
Chromene derivatives as phoshoinositide 3-kinases inhibitors
|
CN107921106B
(zh)
*
|
2015-05-20 |
2023-09-08 |
住友制药株式会社 |
Wt1抗原肽和免疫调节剂的组合用途
|
WO2016198698A2
(en)
|
2015-06-12 |
2016-12-15 |
Cnic Fundación Centro Nacional De Investigaciones Cardiovasculares Carlos Iii |
P38 inhibitors for the treatment and prophylaxis of liver cancer
|
KR102161364B1
(ko)
|
2015-09-14 |
2020-09-29 |
화이자 인코포레이티드 |
LRRK2 억제제로서 이미다조[4,5-c]퀴놀린 및 이미다조[4,5-c][1,5]나프티리딘 유도체
|
US9427439B1
(en)
|
2015-10-26 |
2016-08-30 |
Eip Pharma, Llc |
Methods and compositions for recovery from stroke
|
JP6889493B2
(ja)
|
2015-10-26 |
2021-06-18 |
イーアイピー ファーマ, エルエルシー |
脳卒中からの回復のための方法および組成物
|
EP3383867B1
(en)
|
2015-12-03 |
2021-04-14 |
Chiesi Farmaceutici S.p.A. |
Compounds having muscarinic receptor antagonist and beta2 adrenergic receptor agonist activity
|
EP3394058B1
(en)
|
2015-12-23 |
2020-10-14 |
Chiesi Farmaceutici S.p.A. |
N-[3-(3-{4-[[1,2,4]triazolo[4,3-a]pyridin-6-yloxy]-1,2,3,4-tetrahydro-naphthalen-1-yl} -ureido)-phenyl]-methanesulfonamide derivatives and their use as p38 mapk inhibitors
|
CA3008113A1
(en)
|
2015-12-24 |
2017-06-29 |
The Doshisha |
Drug for treating or preventing disorder caused by tgf-.beta. signals, and application thereof
|
CA3010101A1
(en)
|
2015-12-29 |
2017-07-06 |
Board Of Regents, The University Of Texas System |
Inhibition of p38 mapk for the treatment of cancer
|
AU2017213796A1
(en)
*
|
2016-02-01 |
2018-09-20 |
President And Fellows Of Harvard College |
Small molecules for mouse satellite cell proliferation
|
WO2017134053A1
(en)
|
2016-02-04 |
2017-08-10 |
Chiesi Farmaceutici S.P.A. |
Pyrazole derivatives as phosphoinositide 3-kinases inhibitors
|
WO2017211830A1
(en)
|
2016-06-08 |
2017-12-14 |
Support-Venture Gmbh |
Pharmaceutical combinations for treating cancer
|
GB201611712D0
(en)
|
2016-07-02 |
2016-08-17 |
Hvivo Services Ltd |
Methods and compounds for the treatment or prevention of severe or persistent influenza
|
WO2018148797A1
(en)
|
2017-02-15 |
2018-08-23 |
The University Of Melbourne |
A method of treatment
|
CA3128468A1
(en)
|
2017-10-05 |
2019-04-11 |
Fulcrum Therapeutics, Inc. |
P38 kinase inhibitors reduce dux4 and downstream gene expression for the treatment of fshd
|
US10342786B2
(en)
|
2017-10-05 |
2019-07-09 |
Fulcrum Therapeutics, Inc. |
P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD
|
WO2019103926A1
(en)
|
2017-11-21 |
2019-05-31 |
Saint Louis University |
P38 inhibitors for the treatment of fshd
|
EP3883597A2
(en)
|
2018-11-20 |
2021-09-29 |
Fulcrum Therapeutics, Inc. |
Compositions and methods for increasing fetal hemoglobin and treating sickle cell disease
|
US20220079951A1
(en)
*
|
2018-12-20 |
2022-03-17 |
Saint Louis University |
Bet inhibitors for modulating dux4 expression in fshd
|
JP2022525199A
(ja)
|
2019-03-15 |
2022-05-11 |
フルクラム セラピューティクス,インコーポレイテッド |
Eedおよびprc2調節物質としての大環状アゾロピリジン誘導体
|
UY39417A
(es)
*
|
2020-09-11 |
2022-03-31 |
Arrowhead Pharmaceuticals Inc |
Agentes de arni para inhibir la expresión de dux4, composiciones de dichos agentes, y métodos de uso
|